COLLEGIUM PHARMACEUTICAL, INC — Director's Dealing 2020

Jun 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK: 0001267565
Period of Report: 2020-06-01

Reporting Person: Ciaffoni Joseph (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-01	Common Stock	F	4672	$21.24	Disposed	204515	Direct
2020-06-01	Common Stock	M	64820	$8.22	Acquired	269335	Direct
2020-06-01	Common Stock	S	70576	$21.53	Disposed	198759	Direct
2020-06-01	Common Stock	S	100	$22.08	Disposed	198659	Direct
2020-06-02	Common Stock	S	5761	$20.47	Disposed	192898	Direct
2020-06-02	Common Stock	S	100	$21.3	Disposed	192798	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-01	Stock Option (Right to Purchase)	$8.22	M	64820	Disposed	2027-05-31	Common Stock (64820)	Direct

Footnotes

F1: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019.

F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.05 to $22.02, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (3) and (4).

F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.18 to $20.92, inclusive.

F5: 64,820 shares under the option are exercisable. The option, initially representing a right to purchase a total of 259,283 shares, vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vested and became exercisable on May 31, 2018 and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) at the end of each quarterly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the Issuer.